Moderna voluntarily pressed pause on its request to license its vaccine candidate, mRNA-1083 — which combines vaccines for seasonal influenza and covid and is intended for people over 50 — until it ...

Overview of RNA Therapeutics MarketThe Global RNA Therapeutics Market is valued at USD 10.9 Billion in 2024 and is projected ...